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ABSTRACT
Cervical uterine cancer is the second most frequent female cancer worldwide and a substantial burden for low-income 
societies and the patients themselves. Understanding the molecular mechanisms of metastasis permits the development 
of therapies that limit tumor progression, as well as providing health and social benefits. Pathomorphology is still the basis 
of research and a reference standard for molecular analysis. The aim of our study was to research and critically evaluate 
clinical trials that use new oncological approaches for node-positive cervical cancer to gain an insight into the molecular 
mechanisms of tumor metastasis. Inclusion criteria: node-positive disease at baseline; at least a first phase clinical study 
comprising adult female patients; novel clinical approach (e.g., radiotherapy, immunotherapy, targeted therapy, vaccines, 
radiosurgery); histologic measurement of treatment efficacy (preferably lymph node ultrastaging); and publications in 
English language only. Information sources: US Clinical trials registry, EU Clinical trials register, ISRCTN registry, and Ovid, 
EBSCO and Cochrane Collaboration databases. Access dates: from January 2010 to April 2018. Exclusions: Abstracts that 
did not meet the inclusion criteria or with unreliable data. We collected complete data (e.g., the entire publication associ-
ated with included abstracts, heterogeneity examination of individual studies, and validity measurement of the statistical 
methods used). Results were analyzed in relation to the most recent understanding of the pathogenesis of cervical cancer 
metastasis. We proposed a possible direction for drug treatment of epithelial tumors based on the mechanisms of metastasis.
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INTRODUCTION
Cervical cancer (CC) is the second most common 
female cancer with around 0.5 million cases worldwide 
and an annual upward trend of 0.6%. The median age of 
death is 55 years. CC disproportionately afflicts women in 
low-resource nations where they do not receive adequate 
screening or therapy. The incidence varies from as high as 
100/100000 in unscreened populations to 1–5/100000 in the 
highly screened populations of high-income countries [1]. 
Because a substantial proportion of patients in high-in-
come countries will soon be in the preinvasive stage of CC, 
the main effort should be focused on possible therapies 
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in patients with higher-stage cancers. The clinical factors 
that influence the prognosis for invasive cervical squamous 
carcinoma, the most common CC subtype, are stage of 
disease, age of patient, depth of invasion, volume of tumor, 
and lymphatic or vascular invasion; all of which correlate 
with the risk of lymph node metastasis (LNM) and systemic 
spread [1, 2]. 
Understanding the molecular mechanisms of metastasis 
onset permits the development of therapies that limit tumor 
progression. Pathomorphology is still the basis of research 
and a reference standard for molecular analysis. 
Patients with LNM are candidates for expensive and toxic 
methods of adjuvant treatments. The main treatment mo-
dality is cisplatin-based chemotherapy, which is an alkylat-
ing-like agent that damages the DNA repair process, as well 
as sensitizing CC tissue to radiotherapy [3, 4]. Our study seeks 
to identify newly-available or recently-identified therapies 
indicated in scientific studies.
Objectives
The aim of our study was to research and critically evalu-
ate recent clinical trials of treatment modalities in patients 
with node-positive CC (NPCC) and to identify effective thera-
pies to date. We also focused our analysis on the molecular 
mechanisms of tumor metastasis and current directions in 
developing new therapies.
MATERIAL AND METHODS
Studies Eligibility and Treatment Selection
The material of this review consisted of completed 
clinical studies (clinical trials with published results) con-
cerning not-yet standard methods of treatment (or their 
novel combinations) for patients with NPCC, irrespective of 
their International Federation of Gynecology and Obstetrics 
(FIGO) stage (2009–2018). Only those abstracts of trials and 
completed English language studies, that were reported 
between January 2010 and April 2018 (1st- to 4th-phase 
trials that were ongoing, or finished, or interrupted due 
to unfavourable outcomes) were considered for further 
evaluation. 
The exclusion criteria were a standard treatment pro-
tocol (defined as “platinum-based chemotherapy”), con-
ventional radiation (brachytherapy, intensity modulated 
radiotherapy, teletherapy, other approaches of classical ra-
diation methods), and other drug therapies and treatment 
schedules as recommended by the National Comprehensive 
Cancer Network (NCCN) for an adjuvant, second-line therapy 
or metastatic setting [5]. Our information sources were the 
US Clinical Trials Registry, the EU Clinical Trials Register, the 
ISRCTN Registry, and the Ovid, EBSCO and Cochrane Collab-
oration databases. Where possible, the reference standard 
for each study protocol that we selected, was a histologic 
finding confirming lymph node-positive disease, and in the 
remaining cases, positive lymph nodes were identified by 
imaging techniques. We selected those studies that met 
our eligibility criteria for analysis and the results are shown 
in Table 1, providing information on study phase, level of 
evidence, FIGO stage, recruitment period, type of treatment, 
outcome measures, and results. In addition, we conducted 
a subjective literature research to identify other factors af-
fecting lymph node metastasis in CC that could be targets 
for therapy in the near future. 
Statistical analysis
Metadata analysis tools were not applied because het-
erogeneity of the selected studies was too high. However, 
it was possible to combine issues that were relevant for 
metadata analysis. These are shown in Table 2 in the Results 
section. We used “Strengthening the reporting of obser-
vational studies in epidemiology” (STROBE) as a guide to 
writing the review section of our study [6]. In the systematic 
review we report here, the aggregate data (no individual 
patient data was used) was compared without violating the 
rights of any third parties. 
RESULTS
Eight clinical trials met our further comparative assess-
ment selection criteria, from a total of 911 studies that met 
our entry criteria (Fig. 1 and Tab. 1) [7–14]. Two randomized 
controlled trials (RCT) were identified [12, 14]. Three of the 
eight studies were ultimately ruled out of our final selec-
tion, because they investigated the treatment impact of 
including paraaortic lymph nodes in the irradiation area. 
This therapy is the standard option for radiotherapy in cases 
of CC, although there is no high-quality data proving the 
validity of this procedure. These three excluded articles are 
listed in Appendix A. Further literature search revealed three 
relevant studies pertaining to novel therapeutic approaches 
in NPCC patients [10, 11, 13]. 
As mentioned above in the Methods section, the 
too-high heterogeneity of the study material meant that 
metadata analysis was not possible; however, Table 2 shows 
the selected issues that we were able to prepare for meta-
data analysis.
DISCUSSION
The purpose of our review was to research and critically 
evaluate the results of published scientific clinical studies of 
the past decade, on treatment approaches with advanced, 
node-positive cervical cancer patients. Our additional focus 
was to identify the most promising modalities of treatment 
that are based on the molecular mechanisms of CC metasta-
sis. We were particularly interested in learning whether there 
are yet unknown metastatic mechanisms of, for example, 
338
Ginekologia Polska 2019, vol. 90, no. 6
www. journals.viamedica.pl/ginekologia_polska
CC, that might permit both a better understanding of the 
biology of cancer and consequently, targeted therapies.
The histogenetic origin of all CC cases is from precan-
cerous intraepithelial lesions. Histological variants depend 
in part on their location and their various known reactions 
to hormonal stimuli, and also partly in the variety of the 
activating gene combinations in virally-infected tissues that 
allows for progression from the preinvasive stage to the in-
vasive disease. However, these “gene patterns” are not well 
researched [15]. Genetic profiles of CC (squamous- and ad-
enocarcinomas) indicates positivity for high-risk types 16 and 
18 of human papillomavirus (HPV), and co-expression of 
the p16 protein. The oncogene activation of the p16 gene is 
silenced by DNA methylation, turns the gene off, and plac-
es the developing cancer cells into “metastatic state”. The 
over-expression of p53, in turn, is present in advanced cancers 
[15, 16]. Patients with CC then face genetic susceptibility due 
to they cannot eliminate HPV because of their immunologic 
abnormalities. The literature also raises the issues of familial 
clustering, tobacco-related carcinogenesis and HPV infection, 
immunosuppression (transplantation, human immunode-
ficiency virus infection), human leukocyte antigen [15, 17]. 
From both the functional and ontogenetic points of 
view, CC is seen to spread in a complex network in various 
Table 1. Eligible studies after final search
No Study phase LoE1 FIGO Stage2
Study 
participants
Recruitment 
period
Drug or treatment Main conclusion Reference
1. II II
Not given 
(advanced, 
persistent, 
recurrent)
69 2004–2008
cisplatin plus 
cetuximab
No additional 
benefit of cetuximab 
beyond cisplatin
Farley et al. 
(2011) [7]
2. II III IB2-IVB 25 2006–2011
Multimodal: triapine 
plus cisplatin during 
pelvic radiation 
therapy with boost 
and intracavitary 
brachytherapy
High rates of clinical 
and metabolic 
responses by adding 
3-AP to cisplatin; 
promising results 
put into randomized 
clinical trial∗
Kunos et al. 
(2014) [8]
3. NA III IV 9 2012–2014
Adoptive T-cell 
therapy 
(HPV-TILs)± after 
primary therapy
Uncertain clinical 
benefit
Stevanović et 
al. (2015) [9]
4.
Ib (sub-study of 
KEYNOTE-028 
trial)
III
Not-specified 
(advanced-
recurrent, 
metastatic, 
PD-L1 positive‡)
24 2014–2018 Pembrolizumab
Partial response 
in 17% patients, 
5 patients with 
grade 3 adverse 
events (AEs), 
no grade 4 AEs
Frenel et al. 
2017 [10]
5. II III IIB-IVA 19 2007–2008 Sunitinib
Stable disease 
in 84% patients
Mackay et al. 
2010 [11]
6. II II IVB 228 2008–2011
Pazopanib 
plus lapatinib 
or pazopanib 
monotherapy 
or lapatinib 
monotherapy
78% OS for 
both arms of 
monotherapy, for 
pazopanib 49.7%, 
for lapatinib 44.1%
Monk et al. 
(2011)* [12]
7. II II
Recurrent or 
metastatic
54 2008–2011
Pemetrexed plus 
cisplatin
Pemetrexed 
plus cisplatin 
is competing 
to other regimen 
in the treatment 
of advanced,
persistent, 
or recurrent CUC
Miller et al. 
[13]
8. II III
Recurrent or 
metastatic
69 2010–2012
Cediranib or 
placebo plus 
paclitaxel-
carboplatin 
chemotherapy
1.4 months in time 
to progression 
of experimental 
vs. control arm
Symonds et al. 
(2015) [14]
1Level of Evidence, 2International Federation of Gynecology and Obstetrics; *NCT01835171, •NA — not applicable (±HPV-TILs –T cells selected for Human papilloma virus; 
+3-aminopiridine-2-carboxylaldehyde thiosemicarbazone; ‡PD-L1 — programmed death ligand 1
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directions, including into lymph vessels and nodes [18]. Fur-
thermore, studies have confirmed that up to 25% of early CC 
cases result from primary sites of lymph node metastasis and 
also transport tumor cells into bone marrow [19, 20]. These 
results form a prerequisite for improving our knowledge 
of the biological activity of the disease and its spreading 
mechanisms; in particular, it assists us to locate CC cells in 
the potentially “vulnerable therapeutic areas” of the lymph 
nodes and lymph vessels.
Lymph-node positive cervical cancer is termed “locally 
advanced” irrespective of its FIGO stage. Indeed, FIGO in 
most recent publication, at the time of writing this paper, 
had not included lymph nodes in its staging system, despite 
LNM being a universally accepted prognostic factor and 
recognition that patients presenting with nodal disease 
require urgent treatment. Locally advanced cervical cancer 
(LACC) is a problematic condition in gynecologic oncology 
due to its heterogeneity, seriousness, and issues with the 
current treatment options [21].
Because progress in medical practice is now more rapid 
than the results of scientific research show, we decided the 
retrospective scope of our review should only be in a time 
frame of years 2010–2018 [22]. This view is also confirmed 
by the dissonance between the knowledge of mechanisms 
of LNM and the focus of ongoing studies. 
However, the problematic issue in our study is the sub-
jective selection of entry terms that may not emerge from 
basic research (selection bias). There is limited correlation 
between the results of imaging studies and the surgical 
staging of nodes [23, 24]. Therefore, one of our initial criteria 
was a histopathologic confirmation of LNM.
Our manuscript reports data on completed clinical stud-
ies from April 2011 to April 2018, with a primary focus on 
novel therapies applied in patients with NPCC. Except for the 
study by Farley et al. [7], all the studies we selected involve 
targeted therapies. These studies can be further classified 
into distinct subtypes of a targeted approach, including, but 
not limited to: receptor-based therapy [10–12], disruption 
of metabolic pathways with the so-called “small molecules” 
[8, 12], inhibition of angiogenesis [12, 14], stimulation for 
apoptosis [9, 11–13], and combating cancer stem cells [9]. 
There is overlap in the mechanisms by which the treatment 
drugs function. The breakthrough in cancer treatment in 
recent years is thanks to the so-called immune checkpoint 
inhibitors.
Angiogenesis inhibitors
The first molecular targeting therapy introduced into 
the standard treatment of metastatic or recurrent CC was 
bevacizumab [22]. Bevacizumab is an anti-VEGF (vascular 
endothelial growth factor) monoclonal antibody which acts 
by targeting and inhibiting VEGF. It stops the tumor’s abil-
ity to form new blood vessels through its disruption of the 
activation and proliferation of endothelial cells. In a phase 
III trial by the Gynecologic Oncology Group (GOG 240) the 
addition of bevacizumab to standard chemotherapy regi-
Figure 1. STROBE diagram presenting the process of selecting studies for analysis
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mens (either cisplatin and paclitaxel, or, topotecan and pa-
clitaxel) resulted in a prolonged median overall survival (OS) 
of 3.5 months, a median progression-free survival (PFS), and 
higher response rates [22]. The publication of the results of 
the GOG 240 trial not only changed the standard treatment 
for cervical cancer, but also opened a way for the introduc-
tion of other antiangiogenetic molecular inhibitors to clini-
cal trials. In our analysis we identified two other clinical trials 
which used angiogenesis inhibitors [12, 14]. 
The first of these two mentioned above, the 
NCT00430781 phase II randomized trial, studied the use 
of pazopanib and lapatinib [12]. Pazopanib is a multi-target 
tyrosine kinase inhibitor (TKI) of the vascular endothe-
lial growth factor receptor (VEGFR), the platelet-derived 
growth factor receptor (PDGFR), and the stem cell factor 
receptor (c-KIT). It had been previously approved for the 
treatment of advanced renal cell carcinoma and soft tissue 
sarcomas. Conversely, lapatinib is a TKI that inhibits the 
HER2/neu and epidermal growth factor receptor (EGFR) 
pathways. It is used in combination with other drugs in 
treating patients with breast cancer whose tumors overex-
press HER2. The use of pazopanib in the study cited here 
was associated with improved OS and PFS and confirmed 
the efficacy of using antiangiogenetic agents for advanced 
and recurrent CC. 
The second study referred to above, the CIRCCa trial, 
investigated the use of cediranib in combination with 
chemotherapy in advanced and recurrent CC patients 
[14]. Cediranib is also a kinase inhibitor of VEGF. The addi-
tion of cediranib to carboplatin-paclitaxel chemotherapy 
(compared with the use of a placebo in the control group) 
resulted in higher response rates and a prolonged PFS. 
Unfortunately, the results were not statistically significant 
and the study was closed prematurely due to information 
from the manufacturers of cediranib about negative results 
in other studies using this agent [14].
Receptor-based therapy agents
Pembrolizumab, a major representative in this class of 
drugs, is a monoclonal antibody acting against programmed 
cell death protein 1 (PD-1), encoded by PDCD1 oncogene 
on locus 2q37.3. The PD-1 receptor is expressed on the cells 
of the immune system. Binding ligands to the PD-1 receptor 
inhibits the tumor-specific and cytotoxic activation of im-
mune cells. Dendritic cells can induce T-cell development 
by targeting T lymphocytes through PD-L1 / PD-1 complex, 
increase T-cell tolerance to foreign antigens, or induce ap-
optosis of these cells. The efficacy of pembrolizumab in 
NPCC, among other cancers, was the subject of the large 
KEYONTE 028 study [10]. The study, Frenel et al., of patients 
treated with pembrolizumab, indicated a median duration 
of 5.4 months response for the four patients (17%) who 
achieved a confirmed partial response [10]. These results 
encouraged the same researchers to commence another 
study with pembrolizumab. That ongoing KEYNOTE study 
(no. 826) is observing the effect of chemotherapy with pem-
brolizumab and compared with the use of a placebo in the 
control group in first line treatment for recurrent, persistent 
and metastatic cervical cancer.
Another receptor-based therapy agent, sunitinib, is 
a multi-targeted TKI. The tyrosine kinases family is involved 
in the growth of tumors, neoangiogenesis, and tumor me-
tastasis disease. However, Mackay et al., observed no ob-
jective response in NPCC cases, despite a remarkable PFS 
(3.5 months). Fistula formation emerged as a major concern 
during CC therapy with sunitinib [11].
Pazopanib and lapatinib which are also TKIs, and are 
mentioned above, are mainly effective as antiangiogenetic 
drugs [12].
Small-molecule therapies
Triapine is a ribonucleotide reductase inhibitor that was 
proven to enhance cisplatin-radiation cytotoxicity. In the 
multimodal setting study by Kunos et al., the locoregional 
relapse rate for NPCC (Ib-IIa) and IIIb (FIGO 2009–2018) 
was 4%, the DFS 80% and the OS 82% [8]. Pazopanib and 
lapatinib are also small-molecule therapies.
Apoptosis stimulation
Apoptosis stimulation is the active mechanism of sev-
eral the above-mentioned therapeutic drugs [11, 12, 14]. 
Adoptive T-cell therapy is an autologous cancer-specific 
immunotherapy. A study by Stevanovic et al., showed that 
even a single transfer (infusion) of cancer-derived HPV-re-
active T-cells (tumor infiltrating lymphocytes, TILs) causes 
the long-term cytotoxic effects of either complete or partial 
remission. ATC-based therapies are also examples of cancer 
stem cell blocking [9]. Pemetrexed, an antimetabolite and 
anti-folate, disrupts the metabolite replication mechanism. 
It was proven to be active as antitumor agent yielding a me-
dian PFS of 5.7 months, and a median OS of 12.3 months. 
Cancer stem cell blocking
Adoptive T-cell therapy is used to target HPV-16 or HPV-
18 infected CC cells and therefore stimulate tumor regres-
sion in metastasis settings. This was proven in Stevanovic’s 
et al. study of 9 patients, where 3 participants achieved 
an objective tumor response. In two of these (with adeno-
carcinoma), the objective response lasted 22 and 15 months, 
respectively [9].
Novel targets
Metastasis to the lymph nodes includes several mecha-
nisms and factors which have potential as targets for new 
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Table 3. Overview of molecular mechanisms and factors contributing 
to lymph node metastasis [24]
Mechanisms
• Loss of cell adhesion
• Increased cell mobility and invasiveness
• Entry and survival in the systemic circulation
• Exit to the new tissue
• Possible creation of distant metastases
Factors
• Cytokines
• Hormones
• Growth factors
• Adhesins
• Matrix metalloproteinases
Table 4. Selected factors affecting lymph node metastasis in cervical cancer [26–33]
Factor Its role References
Lysosome- associated 
membrane protein 
3 (LAMP3)
LAMPs are glycosylated proteins present predominantly on lysosome membrane, associated with 
cancer progression and tumor spread. Additionally, LAMp3 is a molecular marker of mature dendritic 
cells.  Its expression is hypoxia regulated. LAMP3 overexpression in primary uterine cervical cancers 
in comparison to normal uterine cervices was shown to be associated with increased metastatic 
potential and with poorer prognosis. 
Nagelkerke at al. 
(2011) [26], 
Alesandrini et al. 
(2011) [27]
Wnt5A
WNT proteins modulate the canonical (β-catenin-dependent) and non-canonical (β-catenin 
independent) pathways and are involved in 
in the regulation of cell growth, proliferation, survival, adhesion and migration.
Wnt5A promotes invasion and proliferation via receptor mediated endocytosis-dependent and 
endocytosis-independent mechanisms, respectively.
Wnt5A-L (337AA) isoform expression is down-, whereas Wnt5A-S (319AA) isoform is up-regulated in 
cervix carcinoma in comparison with normal cervix. Wnt5A-L isoform inhibits, and Wnt5A-S isoform 
promotes cervix carcinoma HeLa cell line proliferation. 
Lin et al. (2014) [28], 
Shojima et al. (2015) 
[29]
miR-20a
MicroRNAs are non-coding RNAs involved in the gene expression regulation via inhibition of 
translation or degradation of target mRNA.
Mir-20a was shown to be up-regulated in cervical cancer tissue in comparison to normal 
controls. Moreover, it was associated with lymph node metastases, tumor size, advanced stage 
and advanced histological grade. In vitro inhibition of miR20a with anti-miR20a was associated with 
decreased cell proliferation, migration and invasion. Moreover, anti-miR20a significantly suppressed 
the growth of cervical cancer xenografts in nude mice. 
Zhao et al. (2015) [30]
miR-411
MiR-411 (targeting STAT-3 transcripts) was shown to be downregulated in cervical cancer tissue and 
cell lines and correlated with tumor size, FIGO, lymph node — and distal metastasis.
Shan et al. (2018) [31]
Survivin, bcl-2 
and KAI1 
Survivin and Bcl2 are tumor promoters via prevention of apoptosis, whereas KAI1 is a tumor 
suppressor, promoting homotypic cell-cell adhesion
Survivin and Bcl2 protein levels were demonstrated to be significantly higher whereas KAI1 levels 
were significantly lower in cervical cancer that in normal cervix, chronic cervicitis or CIN. Moreover, 
survivin expression was positively and KAI1 – negatively associated with lymph node metastasis 
and clinical stage. Bcl2 correlated positively with clinical stage but not with LNM.
Zhou et al. (2015) [32], 
Tsai and Weissman 
(2015) [33]
Centrosomal protein 
55 (CEP55)
CEP55 is essential for cell division. The up- or downregulation can lead to the increased number of 
multinucleated cells. 
CEP55 expression was significantly elevated in cervical cancer tissue compared with adjacent 
non-cancerous tissue and was associated with advanced tumor stage, lymph node metastasis and 
poorer prognosis.
Qi et al. (2018) [34]
therapies (Tab. 3) [25]. The selected factors affecting the 
process of LNM and the possible candidates for further drug 
development are listed in Table 4 [26–33].
Immunotherapy 
— the future of anti-cancer therapy
Regarding cancer progression and metastasis to the 
lymph nodes, the key issue is to understand and control 
the immune mechanisms that enable cancer survival. 
For many years, the role of the immune system in the de-
velopment of cancer was the subject of hot disputes and 
controversy. Currently, many efforts are focused on finding 
the best strategies for combining the blocking effects of the 
CTLA-4 and PD-1 pathways, in combining immunotherapy 
with chemotherapy, and the application of small-molecule 
drug therapies, antineoplastic vaccines, and immunomodu-
latory agents. 
Vaccines are a promising and novel type of drugs. A re-
cent phase-IIB trial showed regression of high-grade CIN 
after the application of VGX-300, a vaccine containing two 
DNA plasmids encoding the E6 and E7 genes of HPV-16 and 
-18 [35]. This type of vaccine therapy induces the activation 
of the antigen presenting cell (APC) by three mechanisms: 
transfection of somatic cells (non-professional APC) with 
the antigen; direct transfection of professional APCs (both 
mediated by major histocompatibility complex, MHC I class 
molecules); and phagocytosis of transfected somatic cells 
by professional APCs (mediated by MHC II class molecules) 
to immunoreactive CD8+ and CD4+ T cells [36]. There is no 
evidence yet for the efficacy of a vaccine therapy against 
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Figure 2. Tumor progression mechanisms and agents acting on these mechanisms in cervical cancer
metastatic cervical cancer. However, systemic organ pen-
etration and the action of immune cells speak for the po-
tential effectiveness of such a vaccine, at least in a setting 
of maintenance therapy.
CONCLUSIONS
The results presented in this review are unsatisfactory 
but are encouraging for further research. Figure 2 sum-
marizes the main available drugs currently used in cancer 
of the cervix with a molecular handle points in terms of 
lymph node metastasis formation. There are other, new 
drug groups that are not listed here, on the horizon: anti-
folate agents (except for pemetrexed), histone deacetylase 
inhibitors, mTOR inhibitors, protein kinase WEE1 inhibitors, 
Notch-signaling inhibitors, heat shock protein 90 interrupt-
ers, and poly ADP ribose inhibitors.
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Currently, considering the limited number of studies and 
the various possible locations of lymph nodes metastases 
contributing to locally advanced uterine cervical cancer 
as a disease with a variety of prognoses and treatments, 
there are only a small number of management types avail-
able. In the first instance, all the current treatments involve 
biological approaches. Secondly, there are many possible 
targets, without counterpart, undergoing clinical trials. 
The delay between the concept and the drug availability of 
the drug therapy for preclinical baseline studies is counted 
in years. Added to this is the claim that fewer than 2% of 
preclinical studies transition to the clinical phase.
Finally, and consequently, it is worth noting that clini-
cal practice is a fire-fighting intervention, instead being 
preventative. Nothing can cure cervical cancer metastases 
better than preventing them from occurring. Therefore, 
vaccination should be globally available and offered to all 
young women.
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